Continuous Renal Replacement Therapy | Figure 1

%27%3e%3cg%20id=%27Group-14%27%20transform=%27translate(13.000000,%20103.176124)%27%3e%3cg%20id=%27Group-Copy-5%27%20transform=%27translate(0.000000,%20182.676124)%27%3e%3crect%20id=%27Rectangle-8%27%20fill=%27%23E2E0DE%27%20x=%270%27%20y=%270%27%20width=%2736%27%20height=%2736%27%20rx=%2718%27%3e%3c/rect%3e%3cpath%20d=%27M28,27.6503435%20C28,22.127496%2023.5228474,17.6503435%2018,17.6503435%20C12.4771525,17.6503435%208,22.127496%208,27.6503435%20M18,16.3472505%20C20.8165136,16.3472505%2023.099749,14.0640151%2023.099749,11.2475015%20C23.099749,8.43098783%2020.8165136,6.1477524%2018,6.1477524%20C15.1834863,6.1477524%2012.9002509,8.43098783%2012.9002509,11.2475015%20C12.9002509,14.0640151%2015.1834863,16.3472505%2018,16.3472505%20Z%27%20id=%27Combined-Shape%27%20fill=%27%23FFFFFF%27%20fill-rule=%27nonzero%27%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)

Continuous Renal Replacement Therapy

Why you should join Figure 1

• Share your knowledge with our global community of healthcare professionals
• Get help from experts in your field
• Learn from our library of real-world cases and quizzes

At ASN Kidney Week 2025, Charmaine E. Lok, MD, MSc presented data from the PISCES trial on November 7. In this randomized, double-blind study of 1,228 adults on maintenance hemodialysis, daily omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation significantly reduced serious cardiovascular events compared with placebo (HR, 0.57; 95% CI, 0.47–0.70; P < 0.0001). Dr. Lok described the findings as “surprising” and suggested the 2:1 EPA-to-DHA ratio may underlie the benefit, offering a simple approach to improve outcomes in this high-risk population.